In a patient with low risk T3N1 stage III colon cancer unable to tolerate CAPOX due to profound GI toxicity, would you switch to FOLFOX and extend to 6 months of adjuvant therapy?

While I certainly agree the problem lies with the capecitabine far more than the oxaliplatin, I would approach this patient a little differently. Consider that we are told that the patient had “profound” diarrhea, and no other toxicity (at least, none is mentioned). That would be a bit unusual for c...

In a patient with a low-risk (T3N1) colon cancer, it is reasonable to treat with 3 months of adjuvant CAPOX or 3-6 months of adjuvant FOLFOX. The subgroup data from the IDEA study show similar efficacy of 3 vs 6 months of FOLFOX in this low-risk subgroup, and NCCN guidelines recognize any of the abo...